Global Leukocyte Surface Antigen CD47 Market Growth 2026-2032
The global Leukocyte Surface Antigen CD47 market size is predicted to grow from US$ 32.28 million in 2025 to US$ 64.38 million in 2032; it is expected to grow at a CAGR of 10.4% from 2026 to 2032.
Leukocyte Surface Antigen CD47 refers to a biologically and commercially defined target centered on the CD47 antigen. In the market, the sellable products are usually not the native antigen in the human body itself, but antibodies, recombinant proteins, assay kits, binding reagents, and preclinical or clinical blocking molecules developed around this target. The native molecule is a broadly expressed glycosylated transmembrane protein on the cell surface; commercial forms are commonly clear to slightly opalescent liquids, lyophilized powders, or pre-coated microplate kits. Structurally, it contains an extracellular immunoglobulin-like domain, multiple transmembrane regions, and a short intracellular tail. Its product composition may include mammalian-cell-expressed recombinant protein, hybridoma-derived or recombinantly expressed monoclonal antibodies, fluorescent or enzyme-conjugated antibodies, and engineered fusion proteins. Leukocyte Surface Antigen CD47 products belong to life-science research reagents, immunoassay raw materials, and oncology immunotherapy target-development materials. Key technical requirements include high purity, lot-to-lot consistency, correct conformation, low endotoxin, defined species reactivity, and validated binding activity. Its functional principle is to detect or modulate the interaction between this antigen and phagocyte receptors, supporting cell phenotyping, tissue staining, antibody screening, binding-kinetics testing, tumor-immunology research, and candidate-drug evaluation.
Market opportunities are mainly driven by the extension of oncology immunology from adaptive immune checkpoints to innate immune checkpoints. Leukocyte Surface Antigen CD47 is linked to phagocytosis-suppressive signaling, so it supports basic research, flow-cytometry detection, tissue staining, antibody screening, and candidate-drug evaluation. As combination therapy, biomarker stratification, and low red-blood-cell binding designs become the focus of development, research antibodies, recombinant proteins, binding-assay materials, and preclinical functional antibodies still have room for steady growth. For suppliers, the key opportunity is not ordinary catalog antibodies alone, but high-consistency, low-endotoxin, clone-defined, cross-species-validated, and functionally blocking product portfolios.
The main challenge is that the target is broadly expressed, making the therapeutic window narrower than many tumor-specific targets. Failures, discontinuations, and clinical holds in representative candidate drugs have reset investor expectations and reduced the credibility of early high-growth assumptions. In therapeutic development, major risks include anemia, platelet effects, red-blood-cell binding, insufficient monotherapy efficacy, complex combination strategies, difficult patient enrollment, and delayed commercialization. The research reagent segment is less directly affected, but when drug pipelines contract, demand for screening reagents and translational-research materials can become more project-driven and volatile.
Downstream demand is expected to become more segmented. Basic research, immunology, hematology, and tumor-microenvironment studies will continue to generate routine purchases of antibodies, recombinant proteins, and assay kits, usually in small-batch and multi-specification formats. Drug-development customers will place greater emphasis on traceable manufacturing, functional validation, low endotoxin, cell-binding activity, and customized compatibility with candidate screening. Future growth is more likely to come from high-quality tool products, companion research materials, preclinical efficacy evaluation, and combination-immunotherapy research, rather than from near-term large-scale commercial drug sales.
LP Information, Inc. (LPI) ' newest research report, the ?Leukocyte Surface Antigen CD47 Industry Forecast? looks at past sales and reviews total world Leukocyte Surface Antigen CD47 sales in 2025, providing a comprehensive analysis by region and market sector of projected Leukocyte Surface Antigen CD47 sales for 2026 through 2032. With Leukocyte Surface Antigen CD47 sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Leukocyte Surface Antigen CD47 industry.
This Insight Report provides a comprehensive analysis of the global Leukocyte Surface Antigen CD47 landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Leukocyte Surface Antigen CD47 portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Leukocyte Surface Antigen CD47 market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Leukocyte Surface Antigen CD47 and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Leukocyte Surface Antigen CD47.
This report presents a comprehensive overview, market shares, and growth opportunities of Leukocyte Surface Antigen CD47 market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Leukocyte Surface Antigen CD47 market?
What factors are driving Leukocyte Surface Antigen CD47 market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Leukocyte Surface Antigen CD47 market opportunities vary by end market size?
How does Leukocyte Surface Antigen CD47 break out by Type, by Application?
Leukocyte Surface Antigen CD47 refers to a biologically and commercially defined target centered on the CD47 antigen. In the market, the sellable products are usually not the native antigen in the human body itself, but antibodies, recombinant proteins, assay kits, binding reagents, and preclinical or clinical blocking molecules developed around this target. The native molecule is a broadly expressed glycosylated transmembrane protein on the cell surface; commercial forms are commonly clear to slightly opalescent liquids, lyophilized powders, or pre-coated microplate kits. Structurally, it contains an extracellular immunoglobulin-like domain, multiple transmembrane regions, and a short intracellular tail. Its product composition may include mammalian-cell-expressed recombinant protein, hybridoma-derived or recombinantly expressed monoclonal antibodies, fluorescent or enzyme-conjugated antibodies, and engineered fusion proteins. Leukocyte Surface Antigen CD47 products belong to life-science research reagents, immunoassay raw materials, and oncology immunotherapy target-development materials. Key technical requirements include high purity, lot-to-lot consistency, correct conformation, low endotoxin, defined species reactivity, and validated binding activity. Its functional principle is to detect or modulate the interaction between this antigen and phagocyte receptors, supporting cell phenotyping, tissue staining, antibody screening, binding-kinetics testing, tumor-immunology research, and candidate-drug evaluation.
Market opportunities are mainly driven by the extension of oncology immunology from adaptive immune checkpoints to innate immune checkpoints. Leukocyte Surface Antigen CD47 is linked to phagocytosis-suppressive signaling, so it supports basic research, flow-cytometry detection, tissue staining, antibody screening, and candidate-drug evaluation. As combination therapy, biomarker stratification, and low red-blood-cell binding designs become the focus of development, research antibodies, recombinant proteins, binding-assay materials, and preclinical functional antibodies still have room for steady growth. For suppliers, the key opportunity is not ordinary catalog antibodies alone, but high-consistency, low-endotoxin, clone-defined, cross-species-validated, and functionally blocking product portfolios.
The main challenge is that the target is broadly expressed, making the therapeutic window narrower than many tumor-specific targets. Failures, discontinuations, and clinical holds in representative candidate drugs have reset investor expectations and reduced the credibility of early high-growth assumptions. In therapeutic development, major risks include anemia, platelet effects, red-blood-cell binding, insufficient monotherapy efficacy, complex combination strategies, difficult patient enrollment, and delayed commercialization. The research reagent segment is less directly affected, but when drug pipelines contract, demand for screening reagents and translational-research materials can become more project-driven and volatile.
Downstream demand is expected to become more segmented. Basic research, immunology, hematology, and tumor-microenvironment studies will continue to generate routine purchases of antibodies, recombinant proteins, and assay kits, usually in small-batch and multi-specification formats. Drug-development customers will place greater emphasis on traceable manufacturing, functional validation, low endotoxin, cell-binding activity, and customized compatibility with candidate screening. Future growth is more likely to come from high-quality tool products, companion research materials, preclinical efficacy evaluation, and combination-immunotherapy research, rather than from near-term large-scale commercial drug sales.
LP Information, Inc. (LPI) ' newest research report, the ?Leukocyte Surface Antigen CD47 Industry Forecast? looks at past sales and reviews total world Leukocyte Surface Antigen CD47 sales in 2025, providing a comprehensive analysis by region and market sector of projected Leukocyte Surface Antigen CD47 sales for 2026 through 2032. With Leukocyte Surface Antigen CD47 sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Leukocyte Surface Antigen CD47 industry.
This Insight Report provides a comprehensive analysis of the global Leukocyte Surface Antigen CD47 landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Leukocyte Surface Antigen CD47 portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Leukocyte Surface Antigen CD47 market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Leukocyte Surface Antigen CD47 and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Leukocyte Surface Antigen CD47.
This report presents a comprehensive overview, market shares, and growth opportunities of Leukocyte Surface Antigen CD47 market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- B-6H12
- ALX-148
- CC-90002
- PSTx-23
- Others
- Anti-CD47 Antibodies
- Recombinant CD47 Proteins
- CD47 Assay Kits
- Others
- Antibodies
- Fusion Proteins
- Small Molecules and Peptides
- Others
- Mammalian Cell Expression Products
- Hybridoma-derived Products
- Microbial Expression Products
- Others
- Lymphoma
- Ovarian Cancer
- Ischemia Reperfusion Injury
- Kindney Transplant Rejection
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Thermo Fisher Scientific
- Merck
- BD Biosciences
- Bio-Techne
- Bio-Rad
- Revvity BioLegend
- Abcam
- Miltenyi Biotec
- Cell Signaling Technology
- Proteintech
- Sino Biological
- ACROBiosystems
- MedChemExpress
- OriGene
- Santa Cruz Biotechnology
- Bio X Cell
- Leinco Technologies
- RayBiotech
- Cytek Biosciences
- Biocare Medical
- Creative Biolabs
- BPS Bioscience
- MyBioSource
- Novus Biologicals
- Aviva Systems Biology
- Bioss
- Innovative Research
- Antibodies.com
- Abbexa
- Arigo Biolaboratories
- Abnova
- CUSABIO
- Elabscience
- Boster Biological Technology
- ABclonal
- Sangon Biotech
- Cloud-Clone
- Akeso
- 3D Medicines
- Fapon Biopharma
- Aurigene Oncology
- ALX Oncology
- ImmuneOncia Therapeutics
- Boehringer Ingelheim
What is the 10-year outlook for the global Leukocyte Surface Antigen CD47 market?
What factors are driving Leukocyte Surface Antigen CD47 market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Leukocyte Surface Antigen CD47 market opportunities vary by end market size?
How does Leukocyte Surface Antigen CD47 break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Leukocyte Surface Antigen CD47 Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Leukocyte Surface Antigen CD47 by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Leukocyte Surface Antigen CD47 by Country/Region, 2021, 2025 & 2032
2.2 Leukocyte Surface Antigen CD47 Segment by Type
2.2.1 B-6H12
2.2.2 ALX-148
2.2.3 CC-90002
2.2.4 PSTx-23
2.2.5 Others
2.2.6 Leukocyte Surface Antigen CD47 Sales by Type
2.2.6.1 Global Leukocyte Surface Antigen CD47 Sales Market Share by Type (2021-2026)
2.2.6.2 Global Leukocyte Surface Antigen CD47 Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Leukocyte Surface Antigen CD47 Sale Price by Type (2021-2026)
2.3 Leukocyte Surface Antigen CD47 Segment by Commercial Product Form
2.3.1 Anti-CD47 Antibodies
2.3.2 Recombinant CD47 Proteins
2.3.3 CD47 Assay Kits
2.3.4 Others
2.3.5 Leukocyte Surface Antigen CD47 Sales by Commercial Product Form
2.3.5.1 Global Leukocyte Surface Antigen CD47 Sales Market Share by Commercial Product Form (2021-2026)
2.3.5.2 Global Leukocyte Surface Antigen CD47 Revenue and Market Share by Commercial Product Form (2021-2026)
2.3.5.3 Global Leukocyte Surface Antigen CD47 Sale Price by Commercial Product Form (2021-2026)
2.4 Leukocyte Surface Antigen CD47 Segment by Molecular Modality
2.4.1 Antibodies
2.4.2 Fusion Proteins
2.4.3 Small Molecules and Peptides
2.4.4 Others
2.4.5 Leukocyte Surface Antigen CD47 Sales by Molecular Modality
2.4.5.1 Global Leukocyte Surface Antigen CD47 Sales Market Share by Molecular Modality (2021-2026)
2.4.5.2 Global Leukocyte Surface Antigen CD47 Revenue and Market Share by Molecular Modality (2021-2026)
2.4.5.3 Global Leukocyte Surface Antigen CD47 Sale Price by Molecular Modality (2021-2026)
2.5 Leukocyte Surface Antigen CD47 Segment by Manufacturing System
2.5.1 Mammalian Cell Expression Products
2.5.2 Hybridoma-derived Products
2.5.3 Microbial Expression Products
2.5.4 Others
2.5.5 Leukocyte Surface Antigen CD47 Sales by Manufacturing System
2.5.5.1 Global Leukocyte Surface Antigen CD47 Sales Market Share by Manufacturing System (2021-2026)
2.5.5.2 Global Leukocyte Surface Antigen CD47 Revenue and Market Share by Manufacturing System (2021-2026)
2.5.5.3 Global Leukocyte Surface Antigen CD47 Sale Price by Manufacturing System (2021-2026)
2.6 Leukocyte Surface Antigen CD47 Segment by Application
2.6.1 Lymphoma
2.6.2 Ovarian Cancer
2.6.3 Ischemia Reperfusion Injury
2.6.4 Kindney Transplant Rejection
2.6.5 Others
2.6.6 Leukocyte Surface Antigen CD47 Sales by Application
2.6.6.1 Global Leukocyte Surface Antigen CD47 Sale Market Share by Application (2021-2026)
2.6.6.2 Global Leukocyte Surface Antigen CD47 Revenue and Market Share by Application (2021-2026)
2.6.6.3 Global Leukocyte Surface Antigen CD47 Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Leukocyte Surface Antigen CD47 Breakdown Data by Company
3.1.1 Global Leukocyte Surface Antigen CD47 Annual Sales by Company (2021-2026)
3.1.2 Global Leukocyte Surface Antigen CD47 Sales Market Share by Company (2021-2026)
3.2 Global Leukocyte Surface Antigen CD47 Annual Revenue by Company (2021-2026)
3.2.1 Global Leukocyte Surface Antigen CD47 Revenue by Company (2021-2026)
3.2.2 Global Leukocyte Surface Antigen CD47 Revenue Market Share by Company (2021-2026)
3.3 Global Leukocyte Surface Antigen CD47 Sale Price by Company
3.4 Key Manufacturers Leukocyte Surface Antigen CD47 Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Leukocyte Surface Antigen CD47 Product Location Distribution
3.4.2 Players Leukocyte Surface Antigen CD47 Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LEUKOCYTE SURFACE ANTIGEN CD47 BY GEOGRAPHIC REGION
4.1 World Historic Leukocyte Surface Antigen CD47 Market Size by Geographic Region (2021-2026)
4.1.1 Global Leukocyte Surface Antigen CD47 Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Leukocyte Surface Antigen CD47 Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Leukocyte Surface Antigen CD47 Market Size by Country/Region (2021-2026)
4.2.1 Global Leukocyte Surface Antigen CD47 Annual Sales by Country/Region (2021-2026)
4.2.2 Global Leukocyte Surface Antigen CD47 Annual Revenue by Country/Region (2021-2026)
4.3 Americas Leukocyte Surface Antigen CD47 Sales Growth
4.4 APAC Leukocyte Surface Antigen CD47 Sales Growth
4.5 Europe Leukocyte Surface Antigen CD47 Sales Growth
4.6 Middle East & Africa Leukocyte Surface Antigen CD47 Sales Growth
5 AMERICAS
5.1 Americas Leukocyte Surface Antigen CD47 Sales by Country
5.1.1 Americas Leukocyte Surface Antigen CD47 Sales by Country (2021-2026)
5.1.2 Americas Leukocyte Surface Antigen CD47 Revenue by Country (2021-2026)
5.2 Americas Leukocyte Surface Antigen CD47 Sales by Type (2021-2026)
5.3 Americas Leukocyte Surface Antigen CD47 Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Leukocyte Surface Antigen CD47 Sales by Region
6.1.1 APAC Leukocyte Surface Antigen CD47 Sales by Region (2021-2026)
6.1.2 APAC Leukocyte Surface Antigen CD47 Revenue by Region (2021-2026)
6.2 APAC Leukocyte Surface Antigen CD47 Sales by Type (2021-2026)
6.3 APAC Leukocyte Surface Antigen CD47 Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Leukocyte Surface Antigen CD47 by Country
7.1.1 Europe Leukocyte Surface Antigen CD47 Sales by Country (2021-2026)
7.1.2 Europe Leukocyte Surface Antigen CD47 Revenue by Country (2021-2026)
7.2 Europe Leukocyte Surface Antigen CD47 Sales by Type (2021-2026)
7.3 Europe Leukocyte Surface Antigen CD47 Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Leukocyte Surface Antigen CD47 by Country
8.1.1 Middle East & Africa Leukocyte Surface Antigen CD47 Sales by Country (2021-2026)
8.1.2 Middle East & Africa Leukocyte Surface Antigen CD47 Revenue by Country (2021-2026)
8.2 Middle East & Africa Leukocyte Surface Antigen CD47 Sales by Type (2021-2026)
8.3 Middle East & Africa Leukocyte Surface Antigen CD47 Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Leukocyte Surface Antigen CD47
10.3 Manufacturing Process Analysis of Leukocyte Surface Antigen CD47
10.4 Industry Chain Structure of Leukocyte Surface Antigen CD47
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Leukocyte Surface Antigen CD47 Distributors
11.3 Leukocyte Surface Antigen CD47 Customer
12 WORLD FORECAST REVIEW FOR LEUKOCYTE SURFACE ANTIGEN CD47 BY GEOGRAPHIC REGION
12.1 Global Leukocyte Surface Antigen CD47 Market Size Forecast by Region
12.1.1 Global Leukocyte Surface Antigen CD47 Forecast by Region (2027-2032)
12.1.2 Global Leukocyte Surface Antigen CD47 Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Leukocyte Surface Antigen CD47 Forecast by Type (2027-2032)
12.7 Global Leukocyte Surface Antigen CD47 Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Thermo Fisher Scientific
13.1.1 Thermo Fisher Scientific Company Information
13.1.2 Thermo Fisher Scientific Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.1.3 Thermo Fisher Scientific Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Thermo Fisher Scientific Main Business Overview
13.1.5 Thermo Fisher Scientific Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.2.3 Merck Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 BD Biosciences
13.3.1 BD Biosciences Company Information
13.3.2 BD Biosciences Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.3.3 BD Biosciences Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 BD Biosciences Main Business Overview
13.3.5 BD Biosciences Latest Developments
13.4 Bio-Techne
13.4.1 Bio-Techne Company Information
13.4.2 Bio-Techne Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.4.3 Bio-Techne Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Bio-Techne Main Business Overview
13.4.5 Bio-Techne Latest Developments
13.5 Bio-Rad
13.5.1 Bio-Rad Company Information
13.5.2 Bio-Rad Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.5.3 Bio-Rad Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Bio-Rad Main Business Overview
13.5.5 Bio-Rad Latest Developments
13.6 Revvity BioLegend
13.6.1 Revvity BioLegend Company Information
13.6.2 Revvity BioLegend Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.6.3 Revvity BioLegend Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Revvity BioLegend Main Business Overview
13.6.5 Revvity BioLegend Latest Developments
13.7 Abcam
13.7.1 Abcam Company Information
13.7.2 Abcam Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.7.3 Abcam Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Abcam Main Business Overview
13.7.5 Abcam Latest Developments
13.8 Miltenyi Biotec
13.8.1 Miltenyi Biotec Company Information
13.8.2 Miltenyi Biotec Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.8.3 Miltenyi Biotec Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Miltenyi Biotec Main Business Overview
13.8.5 Miltenyi Biotec Latest Developments
13.9 Cell Signaling Technology
13.9.1 Cell Signaling Technology Company Information
13.9.2 Cell Signaling Technology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.9.3 Cell Signaling Technology Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Cell Signaling Technology Main Business Overview
13.9.5 Cell Signaling Technology Latest Developments
13.10 Proteintech
13.10.1 Proteintech Company Information
13.10.2 Proteintech Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.10.3 Proteintech Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Proteintech Main Business Overview
13.10.5 Proteintech Latest Developments
13.11 Sino Biological
13.11.1 Sino Biological Company Information
13.11.2 Sino Biological Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.11.3 Sino Biological Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Sino Biological Main Business Overview
13.11.5 Sino Biological Latest Developments
13.12 ACROBiosystems
13.12.1 ACROBiosystems Company Information
13.12.2 ACROBiosystems Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.12.3 ACROBiosystems Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 ACROBiosystems Main Business Overview
13.12.5 ACROBiosystems Latest Developments
13.13 MedChemExpress
13.13.1 MedChemExpress Company Information
13.13.2 MedChemExpress Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.13.3 MedChemExpress Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 MedChemExpress Main Business Overview
13.13.5 MedChemExpress Latest Developments
13.14 OriGene
13.14.1 OriGene Company Information
13.14.2 OriGene Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.14.3 OriGene Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 OriGene Main Business Overview
13.14.5 OriGene Latest Developments
13.15 Santa Cruz Biotechnology
13.15.1 Santa Cruz Biotechnology Company Information
13.15.2 Santa Cruz Biotechnology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.15.3 Santa Cruz Biotechnology Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Santa Cruz Biotechnology Main Business Overview
13.15.5 Santa Cruz Biotechnology Latest Developments
13.16 Bio X Cell
13.16.1 Bio X Cell Company Information
13.16.2 Bio X Cell Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.16.3 Bio X Cell Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Bio X Cell Main Business Overview
13.16.5 Bio X Cell Latest Developments
13.17 Leinco Technologies
13.17.1 Leinco Technologies Company Information
13.17.2 Leinco Technologies Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.17.3 Leinco Technologies Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Leinco Technologies Main Business Overview
13.17.5 Leinco Technologies Latest Developments
13.18 RayBiotech
13.18.1 RayBiotech Company Information
13.18.2 RayBiotech Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.18.3 RayBiotech Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 RayBiotech Main Business Overview
13.18.5 RayBiotech Latest Developments
13.19 Cytek Biosciences
13.19.1 Cytek Biosciences Company Information
13.19.2 Cytek Biosciences Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.19.3 Cytek Biosciences Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Cytek Biosciences Main Business Overview
13.19.5 Cytek Biosciences Latest Developments
13.20 Biocare Medical
13.20.1 Biocare Medical Company Information
13.20.2 Biocare Medical Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.20.3 Biocare Medical Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Biocare Medical Main Business Overview
13.20.5 Biocare Medical Latest Developments
13.21 Creative Biolabs
13.21.1 Creative Biolabs Company Information
13.21.2 Creative Biolabs Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.21.3 Creative Biolabs Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 Creative Biolabs Main Business Overview
13.21.5 Creative Biolabs Latest Developments
13.22 BPS Bioscience
13.22.1 BPS Bioscience Company Information
13.22.2 BPS Bioscience Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.22.3 BPS Bioscience Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 BPS Bioscience Main Business Overview
13.22.5 BPS Bioscience Latest Developments
13.23 MyBioSource
13.23.1 MyBioSource Company Information
13.23.2 MyBioSource Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.23.3 MyBioSource Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 MyBioSource Main Business Overview
13.23.5 MyBioSource Latest Developments
13.24 Novus Biologicals
13.24.1 Novus Biologicals Company Information
13.24.2 Novus Biologicals Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.24.3 Novus Biologicals Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Novus Biologicals Main Business Overview
13.24.5 Novus Biologicals Latest Developments
13.25 Aviva Systems Biology
13.25.1 Aviva Systems Biology Company Information
13.25.2 Aviva Systems Biology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.25.3 Aviva Systems Biology Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.25.4 Aviva Systems Biology Main Business Overview
13.25.5 Aviva Systems Biology Latest Developments
13.26 Bioss
13.26.1 Bioss Company Information
13.26.2 Bioss Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.26.3 Bioss Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.26.4 Bioss Main Business Overview
13.26.5 Bioss Latest Developments
13.27 Innovative Research
13.27.1 Innovative Research Company Information
13.27.2 Innovative Research Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.27.3 Innovative Research Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.27.4 Innovative Research Main Business Overview
13.27.5 Innovative Research Latest Developments
13.28 Antibodies.com
13.28.1 Antibodies.com Company Information
13.28.2 Antibodies.com Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.28.3 Antibodies.com Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.28.4 Antibodies.com Main Business Overview
13.28.5 Antibodies.com Latest Developments
13.29 Abbexa
13.29.1 Abbexa Company Information
13.29.2 Abbexa Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.29.3 Abbexa Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.29.4 Abbexa Main Business Overview
13.29.5 Abbexa Latest Developments
13.30 Arigo Biolaboratories
13.30.1 Arigo Biolaboratories Company Information
13.30.2 Arigo Biolaboratories Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.30.3 Arigo Biolaboratories Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.30.4 Arigo Biolaboratories Main Business Overview
13.30.5 Arigo Biolaboratories Latest Developments
13.31 Abnova
13.31.1 Abnova Company Information
13.31.2 Abnova Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.31.3 Abnova Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.31.4 Abnova Main Business Overview
13.31.5 Abnova Latest Developments
13.32 CUSABIO
13.32.1 CUSABIO Company Information
13.32.2 CUSABIO Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.32.3 CUSABIO Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.32.4 CUSABIO Main Business Overview
13.32.5 CUSABIO Latest Developments
13.33 Elabscience
13.33.1 Elabscience Company Information
13.33.2 Elabscience Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.33.3 Elabscience Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.33.4 Elabscience Main Business Overview
13.33.5 Elabscience Latest Developments
13.34 Boster Biological Technology
13.34.1 Boster Biological Technology Company Information
13.34.2 Boster Biological Technology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.34.3 Boster Biological Technology Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.34.4 Boster Biological Technology Main Business Overview
13.34.5 Boster Biological Technology Latest Developments
13.35 ABclonal
13.35.1 ABclonal Company Information
13.35.2 ABclonal Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.35.3 ABclonal Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.35.4 ABclonal Main Business Overview
13.35.5 ABclonal Latest Developments
13.36 Sangon Biotech
13.36.1 Sangon Biotech Company Information
13.36.2 Sangon Biotech Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.36.3 Sangon Biotech Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.36.4 Sangon Biotech Main Business Overview
13.36.5 Sangon Biotech Latest Developments
13.37 Cloud-Clone
13.37.1 Cloud-Clone Company Information
13.37.2 Cloud-Clone Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.37.3 Cloud-Clone Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.37.4 Cloud-Clone Main Business Overview
13.37.5 Cloud-Clone Latest Developments
13.38 Akeso
13.38.1 Akeso Company Information
13.38.2 Akeso Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.38.3 Akeso Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.38.4 Akeso Main Business Overview
13.38.5 Akeso Latest Developments
13.39 3D Medicines
13.39.1 3D Medicines Company Information
13.39.2 3D Medicines Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.39.3 3D Medicines Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.39.4 3D Medicines Main Business Overview
13.39.5 3D Medicines Latest Developments
13.40 Fapon Biopharma
13.40.1 Fapon Biopharma Company Information
13.40.2 Fapon Biopharma Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.40.3 Fapon Biopharma Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.40.4 Fapon Biopharma Main Business Overview
13.40.5 Fapon Biopharma Latest Developments
13.41 Aurigene Oncology
13.41.1 Aurigene Oncology Company Information
13.41.2 Aurigene Oncology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.41.3 Aurigene Oncology Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.41.4 Aurigene Oncology Main Business Overview
13.41.5 Aurigene Oncology Latest Developments
13.42 ALX Oncology
13.42.1 ALX Oncology Company Information
13.42.2 ALX Oncology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.42.3 ALX Oncology Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.42.4 ALX Oncology Main Business Overview
13.42.5 ALX Oncology Latest Developments
13.43 ImmuneOncia Therapeutics
13.43.1 ImmuneOncia Therapeutics Company Information
13.43.2 ImmuneOncia Therapeutics Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.43.3 ImmuneOncia Therapeutics Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.43.4 ImmuneOncia Therapeutics Main Business Overview
13.43.5 ImmuneOncia Therapeutics Latest Developments
13.44 Boehringer Ingelheim
13.44.1 Boehringer Ingelheim Company Information
13.44.2 Boehringer Ingelheim Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.44.3 Boehringer Ingelheim Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.44.4 Boehringer Ingelheim Main Business Overview
13.44.5 Boehringer Ingelheim Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Leukocyte Surface Antigen CD47 Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Leukocyte Surface Antigen CD47 by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Leukocyte Surface Antigen CD47 by Country/Region, 2021, 2025 & 2032
2.2 Leukocyte Surface Antigen CD47 Segment by Type
2.2.1 B-6H12
2.2.2 ALX-148
2.2.3 CC-90002
2.2.4 PSTx-23
2.2.5 Others
2.2.6 Leukocyte Surface Antigen CD47 Sales by Type
2.2.6.1 Global Leukocyte Surface Antigen CD47 Sales Market Share by Type (2021-2026)
2.2.6.2 Global Leukocyte Surface Antigen CD47 Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Leukocyte Surface Antigen CD47 Sale Price by Type (2021-2026)
2.3 Leukocyte Surface Antigen CD47 Segment by Commercial Product Form
2.3.1 Anti-CD47 Antibodies
2.3.2 Recombinant CD47 Proteins
2.3.3 CD47 Assay Kits
2.3.4 Others
2.3.5 Leukocyte Surface Antigen CD47 Sales by Commercial Product Form
2.3.5.1 Global Leukocyte Surface Antigen CD47 Sales Market Share by Commercial Product Form (2021-2026)
2.3.5.2 Global Leukocyte Surface Antigen CD47 Revenue and Market Share by Commercial Product Form (2021-2026)
2.3.5.3 Global Leukocyte Surface Antigen CD47 Sale Price by Commercial Product Form (2021-2026)
2.4 Leukocyte Surface Antigen CD47 Segment by Molecular Modality
2.4.1 Antibodies
2.4.2 Fusion Proteins
2.4.3 Small Molecules and Peptides
2.4.4 Others
2.4.5 Leukocyte Surface Antigen CD47 Sales by Molecular Modality
2.4.5.1 Global Leukocyte Surface Antigen CD47 Sales Market Share by Molecular Modality (2021-2026)
2.4.5.2 Global Leukocyte Surface Antigen CD47 Revenue and Market Share by Molecular Modality (2021-2026)
2.4.5.3 Global Leukocyte Surface Antigen CD47 Sale Price by Molecular Modality (2021-2026)
2.5 Leukocyte Surface Antigen CD47 Segment by Manufacturing System
2.5.1 Mammalian Cell Expression Products
2.5.2 Hybridoma-derived Products
2.5.3 Microbial Expression Products
2.5.4 Others
2.5.5 Leukocyte Surface Antigen CD47 Sales by Manufacturing System
2.5.5.1 Global Leukocyte Surface Antigen CD47 Sales Market Share by Manufacturing System (2021-2026)
2.5.5.2 Global Leukocyte Surface Antigen CD47 Revenue and Market Share by Manufacturing System (2021-2026)
2.5.5.3 Global Leukocyte Surface Antigen CD47 Sale Price by Manufacturing System (2021-2026)
2.6 Leukocyte Surface Antigen CD47 Segment by Application
2.6.1 Lymphoma
2.6.2 Ovarian Cancer
2.6.3 Ischemia Reperfusion Injury
2.6.4 Kindney Transplant Rejection
2.6.5 Others
2.6.6 Leukocyte Surface Antigen CD47 Sales by Application
2.6.6.1 Global Leukocyte Surface Antigen CD47 Sale Market Share by Application (2021-2026)
2.6.6.2 Global Leukocyte Surface Antigen CD47 Revenue and Market Share by Application (2021-2026)
2.6.6.3 Global Leukocyte Surface Antigen CD47 Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Leukocyte Surface Antigen CD47 Breakdown Data by Company
3.1.1 Global Leukocyte Surface Antigen CD47 Annual Sales by Company (2021-2026)
3.1.2 Global Leukocyte Surface Antigen CD47 Sales Market Share by Company (2021-2026)
3.2 Global Leukocyte Surface Antigen CD47 Annual Revenue by Company (2021-2026)
3.2.1 Global Leukocyte Surface Antigen CD47 Revenue by Company (2021-2026)
3.2.2 Global Leukocyte Surface Antigen CD47 Revenue Market Share by Company (2021-2026)
3.3 Global Leukocyte Surface Antigen CD47 Sale Price by Company
3.4 Key Manufacturers Leukocyte Surface Antigen CD47 Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Leukocyte Surface Antigen CD47 Product Location Distribution
3.4.2 Players Leukocyte Surface Antigen CD47 Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LEUKOCYTE SURFACE ANTIGEN CD47 BY GEOGRAPHIC REGION
4.1 World Historic Leukocyte Surface Antigen CD47 Market Size by Geographic Region (2021-2026)
4.1.1 Global Leukocyte Surface Antigen CD47 Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Leukocyte Surface Antigen CD47 Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Leukocyte Surface Antigen CD47 Market Size by Country/Region (2021-2026)
4.2.1 Global Leukocyte Surface Antigen CD47 Annual Sales by Country/Region (2021-2026)
4.2.2 Global Leukocyte Surface Antigen CD47 Annual Revenue by Country/Region (2021-2026)
4.3 Americas Leukocyte Surface Antigen CD47 Sales Growth
4.4 APAC Leukocyte Surface Antigen CD47 Sales Growth
4.5 Europe Leukocyte Surface Antigen CD47 Sales Growth
4.6 Middle East & Africa Leukocyte Surface Antigen CD47 Sales Growth
5 AMERICAS
5.1 Americas Leukocyte Surface Antigen CD47 Sales by Country
5.1.1 Americas Leukocyte Surface Antigen CD47 Sales by Country (2021-2026)
5.1.2 Americas Leukocyte Surface Antigen CD47 Revenue by Country (2021-2026)
5.2 Americas Leukocyte Surface Antigen CD47 Sales by Type (2021-2026)
5.3 Americas Leukocyte Surface Antigen CD47 Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Leukocyte Surface Antigen CD47 Sales by Region
6.1.1 APAC Leukocyte Surface Antigen CD47 Sales by Region (2021-2026)
6.1.2 APAC Leukocyte Surface Antigen CD47 Revenue by Region (2021-2026)
6.2 APAC Leukocyte Surface Antigen CD47 Sales by Type (2021-2026)
6.3 APAC Leukocyte Surface Antigen CD47 Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Leukocyte Surface Antigen CD47 by Country
7.1.1 Europe Leukocyte Surface Antigen CD47 Sales by Country (2021-2026)
7.1.2 Europe Leukocyte Surface Antigen CD47 Revenue by Country (2021-2026)
7.2 Europe Leukocyte Surface Antigen CD47 Sales by Type (2021-2026)
7.3 Europe Leukocyte Surface Antigen CD47 Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Leukocyte Surface Antigen CD47 by Country
8.1.1 Middle East & Africa Leukocyte Surface Antigen CD47 Sales by Country (2021-2026)
8.1.2 Middle East & Africa Leukocyte Surface Antigen CD47 Revenue by Country (2021-2026)
8.2 Middle East & Africa Leukocyte Surface Antigen CD47 Sales by Type (2021-2026)
8.3 Middle East & Africa Leukocyte Surface Antigen CD47 Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Leukocyte Surface Antigen CD47
10.3 Manufacturing Process Analysis of Leukocyte Surface Antigen CD47
10.4 Industry Chain Structure of Leukocyte Surface Antigen CD47
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Leukocyte Surface Antigen CD47 Distributors
11.3 Leukocyte Surface Antigen CD47 Customer
12 WORLD FORECAST REVIEW FOR LEUKOCYTE SURFACE ANTIGEN CD47 BY GEOGRAPHIC REGION
12.1 Global Leukocyte Surface Antigen CD47 Market Size Forecast by Region
12.1.1 Global Leukocyte Surface Antigen CD47 Forecast by Region (2027-2032)
12.1.2 Global Leukocyte Surface Antigen CD47 Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Leukocyte Surface Antigen CD47 Forecast by Type (2027-2032)
12.7 Global Leukocyte Surface Antigen CD47 Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Thermo Fisher Scientific
13.1.1 Thermo Fisher Scientific Company Information
13.1.2 Thermo Fisher Scientific Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.1.3 Thermo Fisher Scientific Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Thermo Fisher Scientific Main Business Overview
13.1.5 Thermo Fisher Scientific Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.2.3 Merck Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 BD Biosciences
13.3.1 BD Biosciences Company Information
13.3.2 BD Biosciences Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.3.3 BD Biosciences Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 BD Biosciences Main Business Overview
13.3.5 BD Biosciences Latest Developments
13.4 Bio-Techne
13.4.1 Bio-Techne Company Information
13.4.2 Bio-Techne Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.4.3 Bio-Techne Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Bio-Techne Main Business Overview
13.4.5 Bio-Techne Latest Developments
13.5 Bio-Rad
13.5.1 Bio-Rad Company Information
13.5.2 Bio-Rad Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.5.3 Bio-Rad Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Bio-Rad Main Business Overview
13.5.5 Bio-Rad Latest Developments
13.6 Revvity BioLegend
13.6.1 Revvity BioLegend Company Information
13.6.2 Revvity BioLegend Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.6.3 Revvity BioLegend Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Revvity BioLegend Main Business Overview
13.6.5 Revvity BioLegend Latest Developments
13.7 Abcam
13.7.1 Abcam Company Information
13.7.2 Abcam Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.7.3 Abcam Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Abcam Main Business Overview
13.7.5 Abcam Latest Developments
13.8 Miltenyi Biotec
13.8.1 Miltenyi Biotec Company Information
13.8.2 Miltenyi Biotec Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.8.3 Miltenyi Biotec Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Miltenyi Biotec Main Business Overview
13.8.5 Miltenyi Biotec Latest Developments
13.9 Cell Signaling Technology
13.9.1 Cell Signaling Technology Company Information
13.9.2 Cell Signaling Technology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.9.3 Cell Signaling Technology Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Cell Signaling Technology Main Business Overview
13.9.5 Cell Signaling Technology Latest Developments
13.10 Proteintech
13.10.1 Proteintech Company Information
13.10.2 Proteintech Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.10.3 Proteintech Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Proteintech Main Business Overview
13.10.5 Proteintech Latest Developments
13.11 Sino Biological
13.11.1 Sino Biological Company Information
13.11.2 Sino Biological Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.11.3 Sino Biological Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Sino Biological Main Business Overview
13.11.5 Sino Biological Latest Developments
13.12 ACROBiosystems
13.12.1 ACROBiosystems Company Information
13.12.2 ACROBiosystems Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.12.3 ACROBiosystems Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 ACROBiosystems Main Business Overview
13.12.5 ACROBiosystems Latest Developments
13.13 MedChemExpress
13.13.1 MedChemExpress Company Information
13.13.2 MedChemExpress Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.13.3 MedChemExpress Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 MedChemExpress Main Business Overview
13.13.5 MedChemExpress Latest Developments
13.14 OriGene
13.14.1 OriGene Company Information
13.14.2 OriGene Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.14.3 OriGene Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 OriGene Main Business Overview
13.14.5 OriGene Latest Developments
13.15 Santa Cruz Biotechnology
13.15.1 Santa Cruz Biotechnology Company Information
13.15.2 Santa Cruz Biotechnology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.15.3 Santa Cruz Biotechnology Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Santa Cruz Biotechnology Main Business Overview
13.15.5 Santa Cruz Biotechnology Latest Developments
13.16 Bio X Cell
13.16.1 Bio X Cell Company Information
13.16.2 Bio X Cell Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.16.3 Bio X Cell Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Bio X Cell Main Business Overview
13.16.5 Bio X Cell Latest Developments
13.17 Leinco Technologies
13.17.1 Leinco Technologies Company Information
13.17.2 Leinco Technologies Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.17.3 Leinco Technologies Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Leinco Technologies Main Business Overview
13.17.5 Leinco Technologies Latest Developments
13.18 RayBiotech
13.18.1 RayBiotech Company Information
13.18.2 RayBiotech Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.18.3 RayBiotech Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 RayBiotech Main Business Overview
13.18.5 RayBiotech Latest Developments
13.19 Cytek Biosciences
13.19.1 Cytek Biosciences Company Information
13.19.2 Cytek Biosciences Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.19.3 Cytek Biosciences Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Cytek Biosciences Main Business Overview
13.19.5 Cytek Biosciences Latest Developments
13.20 Biocare Medical
13.20.1 Biocare Medical Company Information
13.20.2 Biocare Medical Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.20.3 Biocare Medical Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Biocare Medical Main Business Overview
13.20.5 Biocare Medical Latest Developments
13.21 Creative Biolabs
13.21.1 Creative Biolabs Company Information
13.21.2 Creative Biolabs Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.21.3 Creative Biolabs Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 Creative Biolabs Main Business Overview
13.21.5 Creative Biolabs Latest Developments
13.22 BPS Bioscience
13.22.1 BPS Bioscience Company Information
13.22.2 BPS Bioscience Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.22.3 BPS Bioscience Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 BPS Bioscience Main Business Overview
13.22.5 BPS Bioscience Latest Developments
13.23 MyBioSource
13.23.1 MyBioSource Company Information
13.23.2 MyBioSource Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.23.3 MyBioSource Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 MyBioSource Main Business Overview
13.23.5 MyBioSource Latest Developments
13.24 Novus Biologicals
13.24.1 Novus Biologicals Company Information
13.24.2 Novus Biologicals Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.24.3 Novus Biologicals Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Novus Biologicals Main Business Overview
13.24.5 Novus Biologicals Latest Developments
13.25 Aviva Systems Biology
13.25.1 Aviva Systems Biology Company Information
13.25.2 Aviva Systems Biology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.25.3 Aviva Systems Biology Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.25.4 Aviva Systems Biology Main Business Overview
13.25.5 Aviva Systems Biology Latest Developments
13.26 Bioss
13.26.1 Bioss Company Information
13.26.2 Bioss Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.26.3 Bioss Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.26.4 Bioss Main Business Overview
13.26.5 Bioss Latest Developments
13.27 Innovative Research
13.27.1 Innovative Research Company Information
13.27.2 Innovative Research Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.27.3 Innovative Research Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.27.4 Innovative Research Main Business Overview
13.27.5 Innovative Research Latest Developments
13.28 Antibodies.com
13.28.1 Antibodies.com Company Information
13.28.2 Antibodies.com Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.28.3 Antibodies.com Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.28.4 Antibodies.com Main Business Overview
13.28.5 Antibodies.com Latest Developments
13.29 Abbexa
13.29.1 Abbexa Company Information
13.29.2 Abbexa Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.29.3 Abbexa Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.29.4 Abbexa Main Business Overview
13.29.5 Abbexa Latest Developments
13.30 Arigo Biolaboratories
13.30.1 Arigo Biolaboratories Company Information
13.30.2 Arigo Biolaboratories Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.30.3 Arigo Biolaboratories Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.30.4 Arigo Biolaboratories Main Business Overview
13.30.5 Arigo Biolaboratories Latest Developments
13.31 Abnova
13.31.1 Abnova Company Information
13.31.2 Abnova Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.31.3 Abnova Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.31.4 Abnova Main Business Overview
13.31.5 Abnova Latest Developments
13.32 CUSABIO
13.32.1 CUSABIO Company Information
13.32.2 CUSABIO Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.32.3 CUSABIO Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.32.4 CUSABIO Main Business Overview
13.32.5 CUSABIO Latest Developments
13.33 Elabscience
13.33.1 Elabscience Company Information
13.33.2 Elabscience Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.33.3 Elabscience Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.33.4 Elabscience Main Business Overview
13.33.5 Elabscience Latest Developments
13.34 Boster Biological Technology
13.34.1 Boster Biological Technology Company Information
13.34.2 Boster Biological Technology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.34.3 Boster Biological Technology Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.34.4 Boster Biological Technology Main Business Overview
13.34.5 Boster Biological Technology Latest Developments
13.35 ABclonal
13.35.1 ABclonal Company Information
13.35.2 ABclonal Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.35.3 ABclonal Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.35.4 ABclonal Main Business Overview
13.35.5 ABclonal Latest Developments
13.36 Sangon Biotech
13.36.1 Sangon Biotech Company Information
13.36.2 Sangon Biotech Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.36.3 Sangon Biotech Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.36.4 Sangon Biotech Main Business Overview
13.36.5 Sangon Biotech Latest Developments
13.37 Cloud-Clone
13.37.1 Cloud-Clone Company Information
13.37.2 Cloud-Clone Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.37.3 Cloud-Clone Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.37.4 Cloud-Clone Main Business Overview
13.37.5 Cloud-Clone Latest Developments
13.38 Akeso
13.38.1 Akeso Company Information
13.38.2 Akeso Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.38.3 Akeso Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.38.4 Akeso Main Business Overview
13.38.5 Akeso Latest Developments
13.39 3D Medicines
13.39.1 3D Medicines Company Information
13.39.2 3D Medicines Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.39.3 3D Medicines Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.39.4 3D Medicines Main Business Overview
13.39.5 3D Medicines Latest Developments
13.40 Fapon Biopharma
13.40.1 Fapon Biopharma Company Information
13.40.2 Fapon Biopharma Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.40.3 Fapon Biopharma Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.40.4 Fapon Biopharma Main Business Overview
13.40.5 Fapon Biopharma Latest Developments
13.41 Aurigene Oncology
13.41.1 Aurigene Oncology Company Information
13.41.2 Aurigene Oncology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.41.3 Aurigene Oncology Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.41.4 Aurigene Oncology Main Business Overview
13.41.5 Aurigene Oncology Latest Developments
13.42 ALX Oncology
13.42.1 ALX Oncology Company Information
13.42.2 ALX Oncology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.42.3 ALX Oncology Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.42.4 ALX Oncology Main Business Overview
13.42.5 ALX Oncology Latest Developments
13.43 ImmuneOncia Therapeutics
13.43.1 ImmuneOncia Therapeutics Company Information
13.43.2 ImmuneOncia Therapeutics Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.43.3 ImmuneOncia Therapeutics Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.43.4 ImmuneOncia Therapeutics Main Business Overview
13.43.5 ImmuneOncia Therapeutics Latest Developments
13.44 Boehringer Ingelheim
13.44.1 Boehringer Ingelheim Company Information
13.44.2 Boehringer Ingelheim Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
13.44.3 Boehringer Ingelheim Leukocyte Surface Antigen CD47 Sales, Revenue, Price and Gross Margin (2021-2026)
13.44.4 Boehringer Ingelheim Main Business Overview
13.44.5 Boehringer Ingelheim Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Leukocyte Surface Antigen CD47 Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Leukocyte Surface Antigen CD47 Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of B-6H12
Table 4. Major Players of ALX-148
Table 5. Major Players of CC-90002
Table 6. Major Players of PSTx-23
Table 7. Major Players of Others
Table 8. Global Leukocyte Surface Antigen CD47 Sales by Type (2021-2026) & (K Dose)
Table 9. Global Leukocyte Surface Antigen CD47 Sales Market Share by Type (2021-2026)
Table 10. Global Leukocyte Surface Antigen CD47 Revenue by Type (2021-2026) & ($ million)
Table 11. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Type (2021-2026)
Table 12. Global Leukocyte Surface Antigen CD47 Sale Price by Type (2021-2026) & (US$/Dose)
Table 13. Major Players of Anti-CD47 Antibodies
Table 14. Major Players of Recombinant CD47 Proteins
Table 15. Major Players of CD47 Assay Kits
Table 16. Major Players of Others
Table 17. Global Leukocyte Surface Antigen CD47 Sales by Commercial Product Form (2021-2026) & (K Dose)
Table 18. Global Leukocyte Surface Antigen CD47 Sales Market Share by Commercial Product Form (2021-2026)
Table 19. Global Leukocyte Surface Antigen CD47 Revenue by Commercial Product Form (2021-2026) & ($ million)
Table 20. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Commercial Product Form (2021-2026)
Table 21. Global Leukocyte Surface Antigen CD47 Sale Price by Commercial Product Form (2021-2026) & (US$/Dose)
Table 22. Major Players of Antibodies
Table 23. Major Players of Fusion Proteins
Table 24. Major Players of Small Molecules and Peptides
Table 25. Major Players of Others
Table 26. Global Leukocyte Surface Antigen CD47 Sales by Molecular Modality (2021-2026) & (K Dose)
Table 27. Global Leukocyte Surface Antigen CD47 Sales Market Share by Molecular Modality (2021-2026)
Table 28. Global Leukocyte Surface Antigen CD47 Revenue by Molecular Modality (2021-2026) & ($ million)
Table 29. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Molecular Modality (2021-2026)
Table 30. Global Leukocyte Surface Antigen CD47 Sale Price by Molecular Modality (2021-2026) & (US$/Dose)
Table 31. Major Players of Mammalian Cell Expression Products
Table 32. Major Players of Hybridoma-derived Products
Table 33. Major Players of Microbial Expression Products
Table 34. Major Players of Others
Table 35. Global Leukocyte Surface Antigen CD47 Sales by Manufacturing System (2021-2026) & (K Dose)
Table 36. Global Leukocyte Surface Antigen CD47 Sales Market Share by Manufacturing System (2021-2026)
Table 37. Global Leukocyte Surface Antigen CD47 Revenue by Manufacturing System (2021-2026) & ($ million)
Table 38. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Manufacturing System (2021-2026)
Table 39. Global Leukocyte Surface Antigen CD47 Sale Price by Manufacturing System (2021-2026) & (US$/Dose)
Table 40. Global Leukocyte Surface Antigen CD47 Sale by Application (2021-2026) & (K Dose)
Table 41. Global Leukocyte Surface Antigen CD47 Sale Market Share by Application (2021-2026)
Table 42. Global Leukocyte Surface Antigen CD47 Revenue by Application (2021-2026) & ($ million)
Table 43. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Application (2021-2026)
Table 44. Global Leukocyte Surface Antigen CD47 Sale Price by Application (2021-2026) & (US$/Dose)
Table 45. Global Leukocyte Surface Antigen CD47 Sales by Company (2021-2026) & (K Dose)
Table 46. Global Leukocyte Surface Antigen CD47 Sales Market Share by Company (2021-2026)
Table 47. Global Leukocyte Surface Antigen CD47 Revenue by Company (2021-2026) & ($ millions)
Table 48. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Company (2021-2026)
Table 49. Global Leukocyte Surface Antigen CD47 Sale Price by Company (2021-2026) & (US$/Dose)
Table 50. Key Manufacturers Leukocyte Surface Antigen CD47 Producing Area Distribution and Sales Area
Table 51. Players Leukocyte Surface Antigen CD47 Products Offered
Table 52. Leukocyte Surface Antigen CD47 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 53. New Products and Potential Entrants
Table 54. Market M&A Activity & Strategy
Table 55. Global Leukocyte Surface Antigen CD47 Sales by Geographic Region (2021-2026) & (K Dose)
Table 56. Global Leukocyte Surface Antigen CD47 Sales Market Share Geographic Region (2021-2026)
Table 57. Global Leukocyte Surface Antigen CD47 Revenue by Geographic Region (2021-2026) & ($ millions)
Table 58. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Geographic Region (2021-2026)
Table 59. Global Leukocyte Surface Antigen CD47 Sales by Country/Region (2021-2026) & (K Dose)
Table 60. Global Leukocyte Surface Antigen CD47 Sales Market Share by Country/Region (2021-2026)
Table 61. Global Leukocyte Surface Antigen CD47 Revenue by Country/Region (2021-2026) & ($ millions)
Table 62. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Country/Region (2021-2026)
Table 63. Americas Leukocyte Surface Antigen CD47 Sales by Country (2021-2026) & (K Dose)
Table 64. Americas Leukocyte Surface Antigen CD47 Sales Market Share by Country (2021-2026)
Table 65. Americas Leukocyte Surface Antigen CD47 Revenue by Country (2021-2026) & ($ millions)
Table 66. Americas Leukocyte Surface Antigen CD47 Sales by Type (2021-2026) & (K Dose)
Table 67. Americas Leukocyte Surface Antigen CD47 Sales by Application (2021-2026) & (K Dose)
Table 68. APAC Leukocyte Surface Antigen CD47 Sales by Region (2021-2026) & (K Dose)
Table 69. APAC Leukocyte Surface Antigen CD47 Sales Market Share by Region (2021-2026)
Table 70. APAC Leukocyte Surface Antigen CD47 Revenue by Region (2021-2026) & ($ millions)
Table 71. APAC Leukocyte Surface Antigen CD47 Sales by Type (2021-2026) & (K Dose)
Table 72. APAC Leukocyte Surface Antigen CD47 Sales by Application (2021-2026) & (K Dose)
Table 73. Europe Leukocyte Surface Antigen CD47 Sales by Country (2021-2026) & (K Dose)
Table 74. Europe Leukocyte Surface Antigen CD47 Revenue by Country (2021-2026) & ($ millions)
Table 75. Europe Leukocyte Surface Antigen CD47 Sales by Type (2021-2026) & (K Dose)
Table 76. Europe Leukocyte Surface Antigen CD47 Sales by Application (2021-2026) & (K Dose)
Table 77. Middle East & Africa Leukocyte Surface Antigen CD47 Sales by Country (2021-2026) & (K Dose)
Table 78. Middle East & Africa Leukocyte Surface Antigen CD47 Revenue Market Share by Country (2021-2026)
Table 79. Middle East & Africa Leukocyte Surface Antigen CD47 Sales by Type (2021-2026) & (K Dose)
Table 80. Middle East & Africa Leukocyte Surface Antigen CD47 Sales by Application (2021-2026) & (K Dose)
Table 81. Key Market Drivers & Growth Opportunities of Leukocyte Surface Antigen CD47
Table 82. Key Market Challenges & Risks of Leukocyte Surface Antigen CD47
Table 83. Key Industry Trends of Leukocyte Surface Antigen CD47
Table 84. Leukocyte Surface Antigen CD47 Raw Material
Table 85. Key Suppliers of Raw Materials
Table 86. Leukocyte Surface Antigen CD47 Distributors List
Table 87. Leukocyte Surface Antigen CD47 Customer List
Table 88. Global Leukocyte Surface Antigen CD47 Sales Forecast by Region (2027-2032) & (K Dose)
Table 89. Global Leukocyte Surface Antigen CD47 Revenue Forecast by Region (2027-2032) & ($ millions)
Table 90. Americas Leukocyte Surface Antigen CD47 Sales Forecast by Country (2027-2032) & (K Dose)
Table 91. Americas Leukocyte Surface Antigen CD47 Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 92. APAC Leukocyte Surface Antigen CD47 Sales Forecast by Region (2027-2032) & (K Dose)
Table 93. APAC Leukocyte Surface Antigen CD47 Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 94. Europe Leukocyte Surface Antigen CD47 Sales Forecast by Country (2027-2032) & (K Dose)
Table 95. Europe Leukocyte Surface Antigen CD47 Revenue Forecast by Country (2027-2032) & ($ millions)
Table 96. Middle East & Africa Leukocyte Surface Antigen CD47 Sales Forecast by Country (2027-2032) & (K Dose)
Table 97. Middle East & Africa Leukocyte Surface Antigen CD47 Revenue Forecast by Country (2027-2032) & ($ millions)
Table 98. Global Leukocyte Surface Antigen CD47 Sales Forecast by Type (2027-2032) & (K Dose)
Table 99. Global Leukocyte Surface Antigen CD47 Revenue Forecast by Type (2027-2032) & ($ millions)
Table 100. Global Leukocyte Surface Antigen CD47 Sales Forecast by Application (2027-2032) & (K Dose)
Table 101. Global Leukocyte Surface Antigen CD47 Revenue Forecast by Application (2027-2032) & ($ millions)
Table 102. Thermo Fisher Scientific Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 103. Thermo Fisher Scientific Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 104. Thermo Fisher Scientific Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 105. Thermo Fisher Scientific Main Business
Table 106. Thermo Fisher Scientific Latest Developments
Table 107. Merck Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 108. Merck Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 109. Merck Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 110. Merck Main Business
Table 111. Merck Latest Developments
Table 112. BD Biosciences Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 113. BD Biosciences Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 114. BD Biosciences Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 115. BD Biosciences Main Business
Table 116. BD Biosciences Latest Developments
Table 117. Bio-Techne Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 118. Bio-Techne Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 119. Bio-Techne Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 120. Bio-Techne Main Business
Table 121. Bio-Techne Latest Developments
Table 122. Bio-Rad Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 123. Bio-Rad Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 124. Bio-Rad Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 125. Bio-Rad Main Business
Table 126. Bio-Rad Latest Developments
Table 127. Revvity BioLegend Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 128. Revvity BioLegend Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 129. Revvity BioLegend Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 130. Revvity BioLegend Main Business
Table 131. Revvity BioLegend Latest Developments
Table 132. Abcam Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 133. Abcam Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 134. Abcam Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 135. Abcam Main Business
Table 136. Abcam Latest Developments
Table 137. Miltenyi Biotec Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 138. Miltenyi Biotec Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 139. Miltenyi Biotec Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 140. Miltenyi Biotec Main Business
Table 141. Miltenyi Biotec Latest Developments
Table 142. Cell Signaling Technology Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 143. Cell Signaling Technology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 144. Cell Signaling Technology Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 145. Cell Signaling Technology Main Business
Table 146. Cell Signaling Technology Latest Developments
Table 147. Proteintech Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 148. Proteintech Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 149. Proteintech Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 150. Proteintech Main Business
Table 151. Proteintech Latest Developments
Table 152. Sino Biological Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 153. Sino Biological Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 154. Sino Biological Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 155. Sino Biological Main Business
Table 156. Sino Biological Latest Developments
Table 157. ACROBiosystems Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 158. ACROBiosystems Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 159. ACROBiosystems Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 160. ACROBiosystems Main Business
Table 161. ACROBiosystems Latest Developments
Table 162. MedChemExpress Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 163. MedChemExpress Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 164. MedChemExpress Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 165. MedChemExpress Main Business
Table 166. MedChemExpress Latest Developments
Table 167. OriGene Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 168. OriGene Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 169. OriGene Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 170. OriGene Main Business
Table 171. OriGene Latest Developments
Table 172. Santa Cruz Biotechnology Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 173. Santa Cruz Biotechnology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 174. Santa Cruz Biotechnology Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 175. Santa Cruz Biotechnology Main Business
Table 176. Santa Cruz Biotechnology Latest Developments
Table 177. Bio X Cell Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 178. Bio X Cell Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 179. Bio X Cell Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 180. Bio X Cell Main Business
Table 181. Bio X Cell Latest Developments
Table 182. Leinco Technologies Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 183. Leinco Technologies Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 184. Leinco Technologies Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 185. Leinco Technologies Main Business
Table 186. Leinco Technologies Latest Developments
Table 187. RayBiotech Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 188. RayBiotech Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 189. RayBiotech Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 190. RayBiotech Main Business
Table 191. RayBiotech Latest Developments
Table 192. Cytek Biosciences Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 193. Cytek Biosciences Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 194. Cytek Biosciences Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 195. Cytek Biosciences Main Business
Table 196. Cytek Biosciences Latest Developments
Table 197. Biocare Medical Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 198. Biocare Medical Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 199. Biocare Medical Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 200. Biocare Medical Main Business
Table 201. Biocare Medical Latest Developments
Table 202. Creative Biolabs Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 203. Creative Biolabs Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 204. Creative Biolabs Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 205. Creative Biolabs Main Business
Table 206. Creative Biolabs Latest Developments
Table 207. BPS Bioscience Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 208. BPS Bioscience Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 209. BPS Bioscience Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 210. BPS Bioscience Main Business
Table 211. BPS Bioscience Latest Developments
Table 212. MyBioSource Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 213. MyBioSource Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 214. MyBioSource Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 215. MyBioSource Main Business
Table 216. MyBioSource Latest Developments
Table 217. Novus Biologicals Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 218. Novus Biologicals Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 219. Novus Biologicals Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 220. Novus Biologicals Main Business
Table 221. Novus Biologicals Latest Developments
Table 222. Aviva Systems Biology Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 223. Aviva Systems Biology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 224. Aviva Systems Biology Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 225. Aviva Systems Biology Main Business
Table 226. Aviva Systems Biology Latest Developments
Table 227. Bioss Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 228. Bioss Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 229. Bioss Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 230. Bioss Main Business
Table 231. Bioss Latest Developments
Table 232. Innovative Research Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 233. Innovative Research Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 234. Innovative Research Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 235. Innovative Research Main Business
Table 236. Innovative Research Latest Developments
Table 237. Antibodies.com Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 238. Antibodies.com Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 239. Antibodies.com Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 240. Antibodies.com Main Business
Table 241. Antibodies.com Latest Developments
Table 242. Abbexa Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 243. Abbexa Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 244. Abbexa Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 245. Abbexa Main Business
Table 246. Abbexa Latest Developments
Table 247. Arigo Biolaboratories Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 248. Arigo Biolaboratories Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 249. Arigo Biolaboratories Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 250. Arigo Biolaboratories Main Business
Table 251. Arigo Biolaboratories Latest Developments
Table 252. Abnova Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 253. Abnova Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 254. Abnova Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 255. Abnova Main Business
Table 256. Abnova Latest Developments
Table 257. CUSABIO Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 258. CUSABIO Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 259. CUSABIO Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 260. CUSABIO Main Business
Table 261. CUSABIO Latest Developments
Table 262. Elabscience Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 263. Elabscience Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 264. Elabscience Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 265. Elabscience Main Business
Table 266. Elabscience Latest Developments
Table 267. Boster Biological Technology Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 268. Boster Biological Technology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 269. Boster Biological Technology Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 270. Boster Biological Technology Main Business
Table 271. Boster Biological Technology Latest Developments
Table 272. ABclonal Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 273. ABclonal Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 274. ABclonal Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 275. ABclonal Main Business
Table 276. ABclonal Latest Developments
Table 277. Sangon Biotech Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 278. Sangon Biotech Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 279. Sangon Biotech Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 280. Sangon Biotech Main Business
Table 281. Sangon Biotech Latest Developments
Table 282. Cloud-Clone Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 283. Cloud-Clone Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 284. Cloud-Clone Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 285. Cloud-Clone Main Business
Table 286. Cloud-Clone Latest Developments
Table 287. Akeso Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 288. Akeso Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 289. Akeso Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 290. Akeso Main Business
Table 291. Akeso Latest Developments
Table 292. 3D Medicines Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 293. 3D Medicines Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 294. 3D Medicines Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 295. 3D Medicines Main Business
Table 296. 3D Medicines Latest Developments
Table 297. Fapon Biopharma Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 298. Fapon Biopharma Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 299. Fapon Biopharma Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 300. Fapon Biopharma Main Business
Table 301. Fapon Biopharma Latest Developments
Table 302. Aurigene Oncology Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 303. Aurigene Oncology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 304. Aurigene Oncology Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 305. Aurigene Oncology Main Business
Table 306. Aurigene Oncology Latest Developments
Table 307. ALX Oncology Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 308. ALX Oncology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 309. ALX Oncology Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 310. ALX Oncology Main Business
Table 311. ALX Oncology Latest Developments
Table 312. ImmuneOncia Therapeutics Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 313. ImmuneOncia Therapeutics Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 314. ImmuneOncia Therapeutics Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 315. ImmuneOncia Therapeutics Main Business
Table 316. ImmuneOncia Therapeutics Latest Developments
Table 317. Boehringer Ingelheim Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 318. Boehringer Ingelheim Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 319. Boehringer Ingelheim Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 320. Boehringer Ingelheim Main Business
Table 321. Boehringer Ingelheim Latest Developments
Table 1. Leukocyte Surface Antigen CD47 Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Leukocyte Surface Antigen CD47 Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of B-6H12
Table 4. Major Players of ALX-148
Table 5. Major Players of CC-90002
Table 6. Major Players of PSTx-23
Table 7. Major Players of Others
Table 8. Global Leukocyte Surface Antigen CD47 Sales by Type (2021-2026) & (K Dose)
Table 9. Global Leukocyte Surface Antigen CD47 Sales Market Share by Type (2021-2026)
Table 10. Global Leukocyte Surface Antigen CD47 Revenue by Type (2021-2026) & ($ million)
Table 11. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Type (2021-2026)
Table 12. Global Leukocyte Surface Antigen CD47 Sale Price by Type (2021-2026) & (US$/Dose)
Table 13. Major Players of Anti-CD47 Antibodies
Table 14. Major Players of Recombinant CD47 Proteins
Table 15. Major Players of CD47 Assay Kits
Table 16. Major Players of Others
Table 17. Global Leukocyte Surface Antigen CD47 Sales by Commercial Product Form (2021-2026) & (K Dose)
Table 18. Global Leukocyte Surface Antigen CD47 Sales Market Share by Commercial Product Form (2021-2026)
Table 19. Global Leukocyte Surface Antigen CD47 Revenue by Commercial Product Form (2021-2026) & ($ million)
Table 20. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Commercial Product Form (2021-2026)
Table 21. Global Leukocyte Surface Antigen CD47 Sale Price by Commercial Product Form (2021-2026) & (US$/Dose)
Table 22. Major Players of Antibodies
Table 23. Major Players of Fusion Proteins
Table 24. Major Players of Small Molecules and Peptides
Table 25. Major Players of Others
Table 26. Global Leukocyte Surface Antigen CD47 Sales by Molecular Modality (2021-2026) & (K Dose)
Table 27. Global Leukocyte Surface Antigen CD47 Sales Market Share by Molecular Modality (2021-2026)
Table 28. Global Leukocyte Surface Antigen CD47 Revenue by Molecular Modality (2021-2026) & ($ million)
Table 29. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Molecular Modality (2021-2026)
Table 30. Global Leukocyte Surface Antigen CD47 Sale Price by Molecular Modality (2021-2026) & (US$/Dose)
Table 31. Major Players of Mammalian Cell Expression Products
Table 32. Major Players of Hybridoma-derived Products
Table 33. Major Players of Microbial Expression Products
Table 34. Major Players of Others
Table 35. Global Leukocyte Surface Antigen CD47 Sales by Manufacturing System (2021-2026) & (K Dose)
Table 36. Global Leukocyte Surface Antigen CD47 Sales Market Share by Manufacturing System (2021-2026)
Table 37. Global Leukocyte Surface Antigen CD47 Revenue by Manufacturing System (2021-2026) & ($ million)
Table 38. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Manufacturing System (2021-2026)
Table 39. Global Leukocyte Surface Antigen CD47 Sale Price by Manufacturing System (2021-2026) & (US$/Dose)
Table 40. Global Leukocyte Surface Antigen CD47 Sale by Application (2021-2026) & (K Dose)
Table 41. Global Leukocyte Surface Antigen CD47 Sale Market Share by Application (2021-2026)
Table 42. Global Leukocyte Surface Antigen CD47 Revenue by Application (2021-2026) & ($ million)
Table 43. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Application (2021-2026)
Table 44. Global Leukocyte Surface Antigen CD47 Sale Price by Application (2021-2026) & (US$/Dose)
Table 45. Global Leukocyte Surface Antigen CD47 Sales by Company (2021-2026) & (K Dose)
Table 46. Global Leukocyte Surface Antigen CD47 Sales Market Share by Company (2021-2026)
Table 47. Global Leukocyte Surface Antigen CD47 Revenue by Company (2021-2026) & ($ millions)
Table 48. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Company (2021-2026)
Table 49. Global Leukocyte Surface Antigen CD47 Sale Price by Company (2021-2026) & (US$/Dose)
Table 50. Key Manufacturers Leukocyte Surface Antigen CD47 Producing Area Distribution and Sales Area
Table 51. Players Leukocyte Surface Antigen CD47 Products Offered
Table 52. Leukocyte Surface Antigen CD47 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 53. New Products and Potential Entrants
Table 54. Market M&A Activity & Strategy
Table 55. Global Leukocyte Surface Antigen CD47 Sales by Geographic Region (2021-2026) & (K Dose)
Table 56. Global Leukocyte Surface Antigen CD47 Sales Market Share Geographic Region (2021-2026)
Table 57. Global Leukocyte Surface Antigen CD47 Revenue by Geographic Region (2021-2026) & ($ millions)
Table 58. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Geographic Region (2021-2026)
Table 59. Global Leukocyte Surface Antigen CD47 Sales by Country/Region (2021-2026) & (K Dose)
Table 60. Global Leukocyte Surface Antigen CD47 Sales Market Share by Country/Region (2021-2026)
Table 61. Global Leukocyte Surface Antigen CD47 Revenue by Country/Region (2021-2026) & ($ millions)
Table 62. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Country/Region (2021-2026)
Table 63. Americas Leukocyte Surface Antigen CD47 Sales by Country (2021-2026) & (K Dose)
Table 64. Americas Leukocyte Surface Antigen CD47 Sales Market Share by Country (2021-2026)
Table 65. Americas Leukocyte Surface Antigen CD47 Revenue by Country (2021-2026) & ($ millions)
Table 66. Americas Leukocyte Surface Antigen CD47 Sales by Type (2021-2026) & (K Dose)
Table 67. Americas Leukocyte Surface Antigen CD47 Sales by Application (2021-2026) & (K Dose)
Table 68. APAC Leukocyte Surface Antigen CD47 Sales by Region (2021-2026) & (K Dose)
Table 69. APAC Leukocyte Surface Antigen CD47 Sales Market Share by Region (2021-2026)
Table 70. APAC Leukocyte Surface Antigen CD47 Revenue by Region (2021-2026) & ($ millions)
Table 71. APAC Leukocyte Surface Antigen CD47 Sales by Type (2021-2026) & (K Dose)
Table 72. APAC Leukocyte Surface Antigen CD47 Sales by Application (2021-2026) & (K Dose)
Table 73. Europe Leukocyte Surface Antigen CD47 Sales by Country (2021-2026) & (K Dose)
Table 74. Europe Leukocyte Surface Antigen CD47 Revenue by Country (2021-2026) & ($ millions)
Table 75. Europe Leukocyte Surface Antigen CD47 Sales by Type (2021-2026) & (K Dose)
Table 76. Europe Leukocyte Surface Antigen CD47 Sales by Application (2021-2026) & (K Dose)
Table 77. Middle East & Africa Leukocyte Surface Antigen CD47 Sales by Country (2021-2026) & (K Dose)
Table 78. Middle East & Africa Leukocyte Surface Antigen CD47 Revenue Market Share by Country (2021-2026)
Table 79. Middle East & Africa Leukocyte Surface Antigen CD47 Sales by Type (2021-2026) & (K Dose)
Table 80. Middle East & Africa Leukocyte Surface Antigen CD47 Sales by Application (2021-2026) & (K Dose)
Table 81. Key Market Drivers & Growth Opportunities of Leukocyte Surface Antigen CD47
Table 82. Key Market Challenges & Risks of Leukocyte Surface Antigen CD47
Table 83. Key Industry Trends of Leukocyte Surface Antigen CD47
Table 84. Leukocyte Surface Antigen CD47 Raw Material
Table 85. Key Suppliers of Raw Materials
Table 86. Leukocyte Surface Antigen CD47 Distributors List
Table 87. Leukocyte Surface Antigen CD47 Customer List
Table 88. Global Leukocyte Surface Antigen CD47 Sales Forecast by Region (2027-2032) & (K Dose)
Table 89. Global Leukocyte Surface Antigen CD47 Revenue Forecast by Region (2027-2032) & ($ millions)
Table 90. Americas Leukocyte Surface Antigen CD47 Sales Forecast by Country (2027-2032) & (K Dose)
Table 91. Americas Leukocyte Surface Antigen CD47 Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 92. APAC Leukocyte Surface Antigen CD47 Sales Forecast by Region (2027-2032) & (K Dose)
Table 93. APAC Leukocyte Surface Antigen CD47 Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 94. Europe Leukocyte Surface Antigen CD47 Sales Forecast by Country (2027-2032) & (K Dose)
Table 95. Europe Leukocyte Surface Antigen CD47 Revenue Forecast by Country (2027-2032) & ($ millions)
Table 96. Middle East & Africa Leukocyte Surface Antigen CD47 Sales Forecast by Country (2027-2032) & (K Dose)
Table 97. Middle East & Africa Leukocyte Surface Antigen CD47 Revenue Forecast by Country (2027-2032) & ($ millions)
Table 98. Global Leukocyte Surface Antigen CD47 Sales Forecast by Type (2027-2032) & (K Dose)
Table 99. Global Leukocyte Surface Antigen CD47 Revenue Forecast by Type (2027-2032) & ($ millions)
Table 100. Global Leukocyte Surface Antigen CD47 Sales Forecast by Application (2027-2032) & (K Dose)
Table 101. Global Leukocyte Surface Antigen CD47 Revenue Forecast by Application (2027-2032) & ($ millions)
Table 102. Thermo Fisher Scientific Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 103. Thermo Fisher Scientific Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 104. Thermo Fisher Scientific Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 105. Thermo Fisher Scientific Main Business
Table 106. Thermo Fisher Scientific Latest Developments
Table 107. Merck Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 108. Merck Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 109. Merck Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 110. Merck Main Business
Table 111. Merck Latest Developments
Table 112. BD Biosciences Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 113. BD Biosciences Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 114. BD Biosciences Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 115. BD Biosciences Main Business
Table 116. BD Biosciences Latest Developments
Table 117. Bio-Techne Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 118. Bio-Techne Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 119. Bio-Techne Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 120. Bio-Techne Main Business
Table 121. Bio-Techne Latest Developments
Table 122. Bio-Rad Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 123. Bio-Rad Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 124. Bio-Rad Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 125. Bio-Rad Main Business
Table 126. Bio-Rad Latest Developments
Table 127. Revvity BioLegend Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 128. Revvity BioLegend Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 129. Revvity BioLegend Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 130. Revvity BioLegend Main Business
Table 131. Revvity BioLegend Latest Developments
Table 132. Abcam Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 133. Abcam Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 134. Abcam Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 135. Abcam Main Business
Table 136. Abcam Latest Developments
Table 137. Miltenyi Biotec Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 138. Miltenyi Biotec Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 139. Miltenyi Biotec Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 140. Miltenyi Biotec Main Business
Table 141. Miltenyi Biotec Latest Developments
Table 142. Cell Signaling Technology Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 143. Cell Signaling Technology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 144. Cell Signaling Technology Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 145. Cell Signaling Technology Main Business
Table 146. Cell Signaling Technology Latest Developments
Table 147. Proteintech Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 148. Proteintech Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 149. Proteintech Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 150. Proteintech Main Business
Table 151. Proteintech Latest Developments
Table 152. Sino Biological Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 153. Sino Biological Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 154. Sino Biological Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 155. Sino Biological Main Business
Table 156. Sino Biological Latest Developments
Table 157. ACROBiosystems Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 158. ACROBiosystems Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 159. ACROBiosystems Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 160. ACROBiosystems Main Business
Table 161. ACROBiosystems Latest Developments
Table 162. MedChemExpress Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 163. MedChemExpress Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 164. MedChemExpress Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 165. MedChemExpress Main Business
Table 166. MedChemExpress Latest Developments
Table 167. OriGene Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 168. OriGene Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 169. OriGene Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 170. OriGene Main Business
Table 171. OriGene Latest Developments
Table 172. Santa Cruz Biotechnology Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 173. Santa Cruz Biotechnology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 174. Santa Cruz Biotechnology Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 175. Santa Cruz Biotechnology Main Business
Table 176. Santa Cruz Biotechnology Latest Developments
Table 177. Bio X Cell Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 178. Bio X Cell Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 179. Bio X Cell Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 180. Bio X Cell Main Business
Table 181. Bio X Cell Latest Developments
Table 182. Leinco Technologies Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 183. Leinco Technologies Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 184. Leinco Technologies Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 185. Leinco Technologies Main Business
Table 186. Leinco Technologies Latest Developments
Table 187. RayBiotech Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 188. RayBiotech Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 189. RayBiotech Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 190. RayBiotech Main Business
Table 191. RayBiotech Latest Developments
Table 192. Cytek Biosciences Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 193. Cytek Biosciences Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 194. Cytek Biosciences Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 195. Cytek Biosciences Main Business
Table 196. Cytek Biosciences Latest Developments
Table 197. Biocare Medical Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 198. Biocare Medical Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 199. Biocare Medical Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 200. Biocare Medical Main Business
Table 201. Biocare Medical Latest Developments
Table 202. Creative Biolabs Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 203. Creative Biolabs Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 204. Creative Biolabs Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 205. Creative Biolabs Main Business
Table 206. Creative Biolabs Latest Developments
Table 207. BPS Bioscience Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 208. BPS Bioscience Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 209. BPS Bioscience Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 210. BPS Bioscience Main Business
Table 211. BPS Bioscience Latest Developments
Table 212. MyBioSource Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 213. MyBioSource Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 214. MyBioSource Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 215. MyBioSource Main Business
Table 216. MyBioSource Latest Developments
Table 217. Novus Biologicals Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 218. Novus Biologicals Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 219. Novus Biologicals Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 220. Novus Biologicals Main Business
Table 221. Novus Biologicals Latest Developments
Table 222. Aviva Systems Biology Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 223. Aviva Systems Biology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 224. Aviva Systems Biology Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 225. Aviva Systems Biology Main Business
Table 226. Aviva Systems Biology Latest Developments
Table 227. Bioss Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 228. Bioss Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 229. Bioss Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 230. Bioss Main Business
Table 231. Bioss Latest Developments
Table 232. Innovative Research Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 233. Innovative Research Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 234. Innovative Research Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 235. Innovative Research Main Business
Table 236. Innovative Research Latest Developments
Table 237. Antibodies.com Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 238. Antibodies.com Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 239. Antibodies.com Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 240. Antibodies.com Main Business
Table 241. Antibodies.com Latest Developments
Table 242. Abbexa Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 243. Abbexa Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 244. Abbexa Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 245. Abbexa Main Business
Table 246. Abbexa Latest Developments
Table 247. Arigo Biolaboratories Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 248. Arigo Biolaboratories Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 249. Arigo Biolaboratories Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 250. Arigo Biolaboratories Main Business
Table 251. Arigo Biolaboratories Latest Developments
Table 252. Abnova Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 253. Abnova Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 254. Abnova Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 255. Abnova Main Business
Table 256. Abnova Latest Developments
Table 257. CUSABIO Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 258. CUSABIO Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 259. CUSABIO Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 260. CUSABIO Main Business
Table 261. CUSABIO Latest Developments
Table 262. Elabscience Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 263. Elabscience Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 264. Elabscience Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 265. Elabscience Main Business
Table 266. Elabscience Latest Developments
Table 267. Boster Biological Technology Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 268. Boster Biological Technology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 269. Boster Biological Technology Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 270. Boster Biological Technology Main Business
Table 271. Boster Biological Technology Latest Developments
Table 272. ABclonal Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 273. ABclonal Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 274. ABclonal Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 275. ABclonal Main Business
Table 276. ABclonal Latest Developments
Table 277. Sangon Biotech Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 278. Sangon Biotech Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 279. Sangon Biotech Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 280. Sangon Biotech Main Business
Table 281. Sangon Biotech Latest Developments
Table 282. Cloud-Clone Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 283. Cloud-Clone Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 284. Cloud-Clone Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 285. Cloud-Clone Main Business
Table 286. Cloud-Clone Latest Developments
Table 287. Akeso Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 288. Akeso Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 289. Akeso Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 290. Akeso Main Business
Table 291. Akeso Latest Developments
Table 292. 3D Medicines Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 293. 3D Medicines Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 294. 3D Medicines Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 295. 3D Medicines Main Business
Table 296. 3D Medicines Latest Developments
Table 297. Fapon Biopharma Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 298. Fapon Biopharma Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 299. Fapon Biopharma Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 300. Fapon Biopharma Main Business
Table 301. Fapon Biopharma Latest Developments
Table 302. Aurigene Oncology Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 303. Aurigene Oncology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 304. Aurigene Oncology Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 305. Aurigene Oncology Main Business
Table 306. Aurigene Oncology Latest Developments
Table 307. ALX Oncology Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 308. ALX Oncology Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 309. ALX Oncology Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 310. ALX Oncology Main Business
Table 311. ALX Oncology Latest Developments
Table 312. ImmuneOncia Therapeutics Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 313. ImmuneOncia Therapeutics Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 314. ImmuneOncia Therapeutics Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 315. ImmuneOncia Therapeutics Main Business
Table 316. ImmuneOncia Therapeutics Latest Developments
Table 317. Boehringer Ingelheim Basic Information, Leukocyte Surface Antigen CD47 Manufacturing Base, Sales Area and Its Competitors
Table 318. Boehringer Ingelheim Leukocyte Surface Antigen CD47 Product Portfolios and Specifications
Table 319. Boehringer Ingelheim Leukocyte Surface Antigen CD47 Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 320. Boehringer Ingelheim Main Business
Table 321. Boehringer Ingelheim Latest Developments
LIST OF FIGURES
Figure 1. Picture of Leukocyte Surface Antigen CD47
Figure 2. Leukocyte Surface Antigen CD47 Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Leukocyte Surface Antigen CD47 Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Leukocyte Surface Antigen CD47 Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Leukocyte Surface Antigen CD47 Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Leukocyte Surface Antigen CD47 Sales Market Share by Country/Region (2025)
Figure 10. Leukocyte Surface Antigen CD47 Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of B-6H12
Figure 12. Product Picture of ALX-148
Figure 13. Product Picture of CC-90002
Figure 14. Product Picture of PSTx-23
Figure 15. Product Picture of Others
Figure 16. Global Leukocyte Surface Antigen CD47 Sales Market Share by Type in 2026
Figure 17. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Type (2021-2026)
Figure 18. Product Picture of Anti-CD47 Antibodies
Figure 19. Product Picture of Recombinant CD47 Proteins
Figure 20. Product Picture of CD47 Assay Kits
Figure 21. Product Picture of Others
Figure 22. Global Leukocyte Surface Antigen CD47 Sales Market Share by Commercial Product Form in 2026
Figure 23. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Commercial Product Form (2021-2026)
Figure 24. Product Picture of Antibodies
Figure 25. Product Picture of Fusion Proteins
Figure 26. Product Picture of Small Molecules and Peptides
Figure 27. Product Picture of Others
Figure 28. Global Leukocyte Surface Antigen CD47 Sales Market Share by Molecular Modality in 2026
Figure 29. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Molecular Modality (2021-2026)
Figure 30. Product Picture of Mammalian Cell Expression Products
Figure 31. Product Picture of Hybridoma-derived Products
Figure 32. Product Picture of Microbial Expression Products
Figure 33. Product Picture of Others
Figure 34. Global Leukocyte Surface Antigen CD47 Sales Market Share by Manufacturing System in 2026
Figure 35. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Manufacturing System (2021-2026)
Figure 36. Leukocyte Surface Antigen CD47 Consumed in Lymphoma
Figure 37. Global Leukocyte Surface Antigen CD47 Market: Lymphoma (2021-2026) & (K Dose)
Figure 38. Leukocyte Surface Antigen CD47 Consumed in Ovarian Cancer
Figure 39. Global Leukocyte Surface Antigen CD47 Market: Ovarian Cancer (2021-2026) & (K Dose)
Figure 40. Leukocyte Surface Antigen CD47 Consumed in Ischemia Reperfusion Injury
Figure 41. Global Leukocyte Surface Antigen CD47 Market: Ischemia Reperfusion Injury (2021-2026) & (K Dose)
Figure 42. Leukocyte Surface Antigen CD47 Consumed in Kindney Transplant Rejection
Figure 43. Global Leukocyte Surface Antigen CD47 Market: Kindney Transplant Rejection (2021-2026) & (K Dose)
Figure 44. Leukocyte Surface Antigen CD47 Consumed in Others
Figure 45. Global Leukocyte Surface Antigen CD47 Market: Others (2021-2026) & (K Dose)
Figure 46. Global Leukocyte Surface Antigen CD47 Sale Market Share by Application (2025)
Figure 47. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Application in 2025
Figure 48. Leukocyte Surface Antigen CD47 Sales by Company in 2025 (K Dose)
Figure 49. Global Leukocyte Surface Antigen CD47 Sales Market Share by Company in 2025
Figure 50. Leukocyte Surface Antigen CD47 Revenue by Company in 2025
Figure 1. Picture of Leukocyte Surface Antigen CD47
Figure 2. Leukocyte Surface Antigen CD47 Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Leukocyte Surface Antigen CD47 Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Leukocyte Surface Antigen CD47 Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Leukocyte Surface Antigen CD47 Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Leukocyte Surface Antigen CD47 Sales Market Share by Country/Region (2025)
Figure 10. Leukocyte Surface Antigen CD47 Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of B-6H12
Figure 12. Product Picture of ALX-148
Figure 13. Product Picture of CC-90002
Figure 14. Product Picture of PSTx-23
Figure 15. Product Picture of Others
Figure 16. Global Leukocyte Surface Antigen CD47 Sales Market Share by Type in 2026
Figure 17. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Type (2021-2026)
Figure 18. Product Picture of Anti-CD47 Antibodies
Figure 19. Product Picture of Recombinant CD47 Proteins
Figure 20. Product Picture of CD47 Assay Kits
Figure 21. Product Picture of Others
Figure 22. Global Leukocyte Surface Antigen CD47 Sales Market Share by Commercial Product Form in 2026
Figure 23. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Commercial Product Form (2021-2026)
Figure 24. Product Picture of Antibodies
Figure 25. Product Picture of Fusion Proteins
Figure 26. Product Picture of Small Molecules and Peptides
Figure 27. Product Picture of Others
Figure 28. Global Leukocyte Surface Antigen CD47 Sales Market Share by Molecular Modality in 2026
Figure 29. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Molecular Modality (2021-2026)
Figure 30. Product Picture of Mammalian Cell Expression Products
Figure 31. Product Picture of Hybridoma-derived Products
Figure 32. Product Picture of Microbial Expression Products
Figure 33. Product Picture of Others
Figure 34. Global Leukocyte Surface Antigen CD47 Sales Market Share by Manufacturing System in 2026
Figure 35. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Manufacturing System (2021-2026)
Figure 36. Leukocyte Surface Antigen CD47 Consumed in Lymphoma
Figure 37. Global Leukocyte Surface Antigen CD47 Market: Lymphoma (2021-2026) & (K Dose)
Figure 38. Leukocyte Surface Antigen CD47 Consumed in Ovarian Cancer
Figure 39. Global Leukocyte Surface Antigen CD47 Market: Ovarian Cancer (2021-2026) & (K Dose)
Figure 40. Leukocyte Surface Antigen CD47 Consumed in Ischemia Reperfusion Injury
Figure 41. Global Leukocyte Surface Antigen CD47 Market: Ischemia Reperfusion Injury (2021-2026) & (K Dose)
Figure 42. Leukocyte Surface Antigen CD47 Consumed in Kindney Transplant Rejection
Figure 43. Global Leukocyte Surface Antigen CD47 Market: Kindney Transplant Rejection (2021-2026) & (K Dose)
Figure 44. Leukocyte Surface Antigen CD47 Consumed in Others
Figure 45. Global Leukocyte Surface Antigen CD47 Market: Others (2021-2026) & (K Dose)
Figure 46. Global Leukocyte Surface Antigen CD47 Sale Market Share by Application (2025)
Figure 47. Global Leukocyte Surface Antigen CD47 Revenue Market Share by Application in 2025
Figure 48. Leukocyte Surface Antigen CD47 Sales by Company in 2025 (K Dose)
Figure 49. Global Leukocyte Surface Antigen CD47 Sales Market Share by Company in 2025
Figure 50. Leukocyte Surface Antigen CD47 Revenue by Company in 2025
